Brief: Coeptis Therapeutics Announces Intent To Acquire Tlr5 Agonist Platform

Statera Biopharma

13/04/2022 12:17

April 13 (Reuters) - Coeptis Therapeutics Inc  COEP.PK :
    * COEPTIS THERAPEUTICS ANNOUNCES INTENT TO ACQUIRE TLR5
AGONIST
PLATFORM, INCLUDING CLINICAL-STAGE ASSET ENTOLIMOD, FROM STATERA
BIOPHARMA
    * COEPTIS - PARTIES HAVE AGREED TO EXCLUSIVITY PERIOD
THROUGH DATE
THAT IS 30 DAYS AFTER FIRST DRAFT OF AGREEMENT IS AVAILABLE TO
REVIEW BY BOTH PARTIES
    * COEPTIS THERAPEUTICS INC - WILL AGREE TO PAY STATERA
BIOPHARMA
SIX MILLION USD AND REVENUE-BASED MILESTONE PAYMENTS

Source text for Eikon:  ID:nPnL2dc5a 
Further company coverage:  COEP.PK 

 ((reuters.briefs@thomsonreuters.com;))